Monday, December 31, 2012

Vomiting Larry And His Aerosolized Norovirus

image

Credit UK’s Health & Safety Laboratory

 

# 6812

 


Sounding vaguely like an invention lifted from one the Tom Swift books of my youth (e.g. Tom Swift and His Atomic Earth Blaster, Tom Swift and His Electric Rifle), Vomiting Larry is a dummy that . . . well, vomits.

 
All in the name of science, of course.

 

In order to test how well (and how far) Norovirus (aka `The Winter Vomiting Bug’) can spread through the air, scientists have created a dummy that spews. A move, I suspect, prompted primarily by a lack of willing  human volunteers for this study.

  

By adding a florescent dye marker to Larry’s `vomitus’, researchers at the UK’s Health & Safety Laboratory have determined that droplets – too small to be readily seen – can end up as far as 3 meters away from the source.

 

Vomiting Larry featured on the BBC website

noravirus

Winter Vomiting bug has been very much in the news of late due to the recent major outbreaks of norovirus, which causes this illness. A recent article on the BBC news website has highlighted the work that the Health and Safety Laboratory has done to establish the extent with which the surrounding environment becomes contaminated when an individual vomits.

 

This is an important consideration for infection control during outbreaks of norovirus where the key symptom is projectile (forced) vomiting. Catherine Makison of HSL's Occupational Hygiene Unit has developed a humanoid simulated vomiting system affectionately known as "Vomiting Larry".

 

"Larry" was primed with a vomitus substitute (to which a fluorescent marker was added so as to identify even small splashes post vomiting), and simulated vomiting was carried out. As the BBC video shows graphically, these tests demonstrated the full extent of room contamination post vomiting and that small droplets can spread over three metres from the "Larry" system, which are not easily visible under standard white hospital lighting.

 

HSL studies have shown that Norovirus can be isolated from these small droplets at concentrations capable of causing an infection. This information might highlight why this robust and highly infectious virus is transmitted between people so readily.

 

The outcomes of these studies have contributed to reviews of healthcare guidance in hospitals and are due to be published in relevant journals in the near future.


 

The role of direct aerosolized human-to-human transmission of norovirus remains less than clear, although there are numerous anecdotal reports that suggest that it happens.

 

The CDC – in a an MMWR report from 2011 called Updated Norovirus Outbreak Management and Disease Prevention Guidelines describes transmission thusly:

 

Transmission

Norovirus is extremely contagious, with an estimated infectious dose as low as 18 viral particles (41), suggesting that approximately 5 billion infectious doses might be contained in each gram of feces during peak shedding. Humans are the only known reservoir for human norovirus infections, and transmission occurs by three general routes: person-to-person, foodborne, and waterborne.

 

Person-to-person transmission might occur directly through the fecal-oral route, by ingestion of aerosolized vomitus, or by indirect exposure via fomites or contaminated environmental surfaces.

 

 

And last May, in Norovirus: The Gift That Keeps On Giving, we looked at an incident involving a girl’s soccer team where 17 girls were exposed via a reusable grocery bag, likely contaminated from an airborne route.

 

image

 

While one of the keys to prevention is good hand hygiene, unlike with many other bacteria and viruses, alcohol gel doesn’t do a particularly good job of killing the virus (see CMAJ: Hand Sanitizers May Be `Suboptimal’ For Preventing Norovirus).

 

Which makes a good old fashion hand scrubbing with soap and water the best preventative.

 

As new studies that show the aerosolized spread of noroviruses are published, hospital infection control policies may need to revisit the use of facemasks for HCWs caring for infected patients.

Study: Self-Administered Vaccines In Adults

image

LAIV nasal syringe – Credit CDC PHIL 

 

# 6811

 

Beyond the difficulties of producing billions of doses of an emergency pandemic influenza vaccine, one of the logistical nightmares is how to best deploy them. The standard solutions – where vaccination centers are set up in public venues, pharmacies, and clinics – have some serious downsides.

 

Queuing hundreds of people together for hours during a pandemic is a good way to spread a virus further. And there are likely to be crowd control and security issues in some places as well.

 

During the 1976 Swine flu scare (see Deja Flu, All Over Again), I was one of thousands of health care workers around the country who were dragooned into providing pandemic flu shots. The logistics of vaccinating millions of people – even without a pandemic raging – were daunting.

image

Yes, that’s me in 1976. I and swear to this very day, that lady was making that face before I gave her the shot.

 

One solution –  made possible by the development of an  LAIV (Live attenuated Influenza Vaccine) – would be to have people self inoculate themselves at home. 

 

LAIV vaccines – unlike the standard flu shot - are delivered via a nasal spray, not a needle.

 

The CDC describes the major differences between the TIV (Trivalent Influenza Vaccine) shot, and the LAIV nasal spray as follows:

 

Major Differences Between TIV and LAIV

Influenza Prevention and Control Recommendations

Published for the 2010-11 Influenza Season; Adapted for the 2012-13 Influenza Season

Trivalent inactivated influenza vaccine (TIV) contains inactivated viruses and thus cannot cause influenza. Live-attenuated influenza vaccine (LAIV) contains live attenuated influenza viruses that have the potential to cause mild signs or symptoms related to vaccine virus infection (e.g., rhinorrhea, nasal congestion, fever, or sore throat). LAIV is administered intranasally by sprayer, whereas TIV is administered intramuscularly or intradermally by injection.

LAIV is licensed for use among nonpregnant persons aged 2-49 years; safety has not been established in persons with underlying medical conditions that confer a higher risk for influenza complications. TIV is licensed for use among persons 6 months and older, including those who are healthy and those with chronic medical conditions.

 

While not suitable for everyone, LAIVs could be used to inoculate a large segment of the population during an influenza pandemic, without the need of a Health care worker. 

 

All of which brings us to a study, recently published in the journal Vaccine (abstract slightly reparagraphed for readability), which looks at:

 

 

The safety and effectiveness of self-administration of intranasal live attenuated influenza vaccine in adults.

 

Ambrose CS, Wu X.

 

Vaccine. 2012 Dec 19. pii: S0264-410X(12)01798-7. doi: 10.1016/j.vaccine.2012.12.028.

Source

MedImmune, LLC, Gaithersburg, MD, USA. Electronic address: ambrosec@medimmune.com.

Abstract

Intranasal live attenuated influenza vaccine (LAIV) has potential for self-administration (SA) by adults and adolescents, which could save time and cost in mass vaccination settings. Participants in a study of LAIV in adults (n=4561) selected either SA or health care provider (HCP) administration and were followed for febrile illness during the influenza season.

More LAIV recipients chose SA-LAIV (72%) than HCP-LAIV (28%). Overall, 97% of SA-LAIV and 98% of HCP-LAIV recipients had no problems with vaccine administration. Four of 13 study sites enrolled more than 50 subjects in both cohorts. Overall and for these 4 sites, illness incidence was similar with SA-LAIV and HCP-LAIV.

Solicited reactogenicity events and adverse events through 7 days post vaccination were comparable for SA-LAIV and HCP-LAIV recipients; both groups exhibited increased runny nose, sore throat, and cough relative to placebo recipients. SA-LAIV and HCP-LAIV appeared similarly effective against influenza-like illness and had comparable safety profiles.

 

CIDRAP NEWS  summarized these findings last week in their Flu News Scan.

 

Study: Smooth sailing for self-administered LAIV flu vax


Self-administered intranasal live attenuated influenza vaccine (LAIV) is as safe and effective as that administered by health providers, according to recent analysis of data from a randomized, placebo-controlled study conducted in 1997 and 1998.

The study, which explored differences in administration and was funded by MedImmune, the maker of Flumist, appeared in the Dec 20 online edition of Vaccine. Self-administered flu vaccines could be useful in a pandemic mass immunization setting and could be a tool for making vaccination more efficient and less costly, the authors say.

<SNIP>

The research group found no significant difference in illness incidence between the two groups and observed comparable levels of reactions and adverse events 7 days after vaccination.
Dec 20 Vaccine
abstract

 

LAIVs are normally shipped  and stored at 35°F--46°F  (cite) - which makes mailing them problematic - but they could be easily distributed via drive thru windows or hand delivered to homes in neighborhoods.

 

LAIVs are particularly attractive during a pandemic because they can be produced in much larger quantities than Inactivated vaccines.

 

But there remain some questions regarding their effectiveness in adults, compared to the TIV (see Study: Nasal Flu Vaccines Generally Less Effective Than Shots In Adults).

 

Caveat: this study was based on seasonal flu vaccine strains used in the middle of the last decade, not on a newly emergent pandemic strain, and so the results may not be fully applicable.

 

Nevertheless, self-administered LAIVs have the potential to streamline vaccine delivery to a significant portion of the population during the next influenza pandemic. And with a novel flu, the quicker you can increase the levels of community immunity, the sooner the crisis will begin to abate.

Sunday, December 30, 2012

HHMI’s Holiday Lecture Series: 2012

image

Credit HHMI


# 6810

 

A couple of years ago I highlighted an online (and freeholiday lecture series  offered by HHMI (Howard Hughes Medical Institute) that focused on Infectious Diseases. These four (roughly 1 hour lectures) were geared for and delivered to an audience of high school science students.

 

Which means that . . . while informative . . .  you didn’t have to be a full fledged microbiologist or virologist in order to follow along.

 

These lecture series are a yearly event, and over the past 18 years they have focused on a variety of topics, including: Cancer, Genomics, Biodiversity, Immunology, Neuroscience, and Infectious Diseases.

 

This year, the focus is on our changing planet, with four lectures available.

 

2012 Holiday Lectures

Changing Planet: Past, Present, Future

The 2012 Holiday Lectures are viewable via Flash streaming (720p HD or 360p SD) or in an iOS MP4 download (360p SD) compatible with iPhone, iPod, and iPad.

Lecture 1: The Deep History of a Living Planet, by Andrew Knoll, Ph.D.


 Lecture 2: Building Scientific Knowledge: The Story of Plate Tectonics, by Naomi Oreskes, Ph.D.


 Lecture 3: Earth's Climate: Back to the Future, by Daniel Schrag, Ph.D.


 Lecture 4: Climate Change: How Do We Know We're Not Wrong?, by Naomi Oreskes, Ph.D.
 


You’ll find a variety of lecture series in the archives, along with a number of `informal talks’.

 

These videos are a wonderful resource, with dozens of hours available on subjects ranging from genetics to anthropology, and everything in between.

 

The rest of the Howard Hughes Medical Institute  website is well worth exploring as well, for it contains numerous short science films, virtual laboratories, and interactive mini-lessons, all designed to feed your `inner science geek’.

 

Many of these videos, lectures, and podcasts are also accessible via iTunes.

 

Highly recommended, whether you are a young student just starting out, or an old science geek like myself.

Saturday, December 29, 2012

CDC FluView Week 51

image

 

# 6809

 


With the Christmas holidays each year usually comes some delays in surveillance and reporting on influenza, so this week we have no FluWatch report from Canada.  According to an email sent by PHAC, `data for weeks 51 and 52 will be published in a combined report on Friday, 4 January 2013.’

 

The CDC’s FluView report, issued on Friday, reflects a drop in the number of influenza-positive tests reported by the WHO/NREVSS collaborating laboratories, but this is likely more an artifact of reduced holiday testing & reporting than a significant drop in flu activity.

INFLUENZA Virus Isolated

A summary of this weeks FluView Report states:

012-2013 Influenza Season Week 51 ending December 22, 2012

All data are preliminary and may change as more reports are received.

Synopsis:

During week 51 (December 16-22), influenza activity increased in the U.S.

  • Viral Surveillance: Of 6,234 specimens tested and reported by U.S. World Health Organization (WHO) and National Respiratory and Enteric Virus Surveillance System (NREVSS) collaborating laboratories in week 51, 1,846 (29.6%) were positive for influenza.
  • Pneumonia and Influenza Mortality: The proportion of deaths attributed to pneumonia and influenza (P&I) was below the epidemic threshold.
  • Influenza-Associated Pediatric Deaths: Eight influenza-associated pediatric deaths were reported. Three were associated with influenza B viruses, 3 were associated with influenza A (H3) viruses, and 2 were associated with influenza A viruses for which the subtype was not determined.
  • Outpatient Illness Surveillance: The proportion of outpatient visits for influenza-like illness (ILI) was 4.2%; above the national baseline of 2.2%. Nine of 10 regions reported ILI above region-specific baseline levels. New York City and 16 states experienced high ILI activity; 8 states experienced moderate ILI activity; 10 states experienced low ILI activity; 14 states experienced minimal ILI activity, and the District of Columbia and 2 states had insufficient data.
  • Geographic Spread of Influenza: Thirty-one states reported widespread geographic influenza activity; 14 states reported regional activity; the District of Columbia and 3 states reported local activity; 2 states reported sporadic activity; Guam reported no influenza activity, and Puerto Rico and the U.S. Virgin Islands did not report.

While flu activity (red line) remains lower (so far) than the peak we saw during the moderately severe 2007-08 season (blue line), the following chart illustrates the early start to the season.

 

image

 

 

The number of pediatric influenza fatalities jumped by 8 this week, to a total of 16 this year, and  Pneumonia and Influenza (P&I) Mortality remains below the epidemic level. Both of these numbers tend to be lagging indicators, however.

 

image

 

 

While flu season is certainly underway across much of the nation, some states have yet to report significant activity.

 

The peak of the season may still be a month or more away, meaning there is still time to get that flu shot. Earlier this week  the CDC sent out the following reminder:

image

Study: Statins & Cerebral Malaria

image

Photo Credit CDC

 

# 6808

 

 

Increasingly, statins – common cholesterol lowering drugs – are being looked at for their inflammation-reducing properties in the treatment of other diseases.

 

Long time readers of this blog will recall that Dr. David Fedson - former Professor of Medicine at the University of Virginia School of Medicine and formerly Director of Medical Affairs, Aventis Pasteur MSD – has advocated research into the potential role of low-cost statins during an influenza pandemic (see Lancet: David Fedson On Statins For Pandemic Influenza).

 

For more on statins, and how they might be used against pandemic influenza, you may wish to revisit:

 

Study: Statins, Influenza, & Mortality

Another Study On Statins And Pneumonia

Dr. David Fedson: The Case For Using Statins In A Pandemic

Statins Revisited

 

A couple of years ago we saw a video presentation at the 2010 ICAAC Conference called A Role for Statins in Infectious Disease? #ICAAC) (excerpt below).

 

Statins are well-known as a class of drugs that are used to help lower cholesterol but recent evidence suggests they might be good for more than your heart. They may play a role in preventing and treating certain bacterial infections including pneumonia and sepsis. Presenters at ICAAC discuss the latest research on the potential of these drugs.

  • Reimar Thomsen, Aarhus University Hospital, Aalborg, Denmark
  • Matthew Falagas, Alfa Institute of Biomedical Sciences, Athens, Greece
  • Nasia Safdar, University of Wisconsin, Madison, WI, United States

 

These presenters suggest that statins may directly affect viruses and fungi, as well as help dampen the body’s inflammatory response. One study discussed found a 30% reduction in 30-day pneumonia mortality among patients already on statins.

 

The caveat being that much of the evidence for statins efficacy comes from in vitro studies, or observational studies that can sometimes be influenced by what is known as the `healthy user bias’.  

 

Simply put, patients who are already on statins when they develop pneumonia, sepsis, or influenza may be more likely to have a healthy lifestyle than those not on statins, potentially skewing the results.

 

Still, the results to date have been intriguing, if not totally convincing.

 

Which brings us to a a new study, appearing in PloS Pathogens, that looks at the potential role of statins in the treatment of cerebral Malaria.

 

According to the WHO:

There were about 219 million cases of malaria in 2010 and an estimated 660 000 deaths. Africa is the most affected continent: about 90% of all malaria deaths occur there.

 

Between 2000 and 2010, malaria mortality rates fell by 26% around the world. In the WHO African Region the decrease was 33%. During this period, an estimated 1.1 million malaria deaths were averted globally, primarily as a result of a scale-up of interventions.

 


Rarely mentioned in all of these figures are the (often life-long) neurological sequelae that cerebral malaria may produce, particularly among children.

 

These may include blindness, epilepsy, decreased motor skills, hearing impairment, aphasia (loss of speech), and behavioral problems, as noted in the following BMC Research Note.

 

 

Severe neurological sequelae and behaviour problems after cerebral malaria in Ugandan children

Richard Idro, Angelina Kakooza-Mwesige, Stephen Balyejjussa, Grace Mirembe, Christine Mugasha, Joshua Tugumisirize and Justus Byarugaba

Conclusions

In addition to previously described neurological and cognitive sequelae, severe behaviour problems may follow cerebral malaria in children. The observed differences in patterns of sequelae may be due to different pathogenic mechanisms, brain regions affected or extent of injury. Cerebral malaria may be used as a new model to study the pathogenesis of ADHD.

 

The PloS Pathogens study, which looks at the potential use of statins for cerebral malaria in a murine (mouse) model, involved infecting lab mice with the malaria parasite, and then treating half of them with just chloroquine, and the other half with chloroquine and Lovastatin. 

 

Mice that received the combination treatment saw a significantly reduced rate of post-infection cognitive dysfunction.

 

Statins Decrease Neuroinflammation and Prevent Cognitive Impairment after Cerebral Malaria

Patricia A. Reis mail, Vanessa Estato, Tathiany I. da Silva, Joana C. d'Avila, Luciana D. Siqueira, Edson F. Assis, Patricia T. Bozza, Fernando A. Bozza, Eduardo V. Tibiriça, Guy A. Zimmerman, Hugo C. Castro-Faria-Neto

Author Summary

Cerebral malaria (CM) is the direst consequence of Plasmodium falciparum infection. Cognitive impairment is a common sequela in children surviving CM. Identification of adjunctive therapies that reduce the complications of CM in survivors is a priority. Statins have been suggested for the treatment of neuroinflammatory disorders due to their pleiotropic effects.

 

Here, we examined the effects of lovastatin on neuroinflammation in experimental CM, and its effect on the prevention of cognitive impairment. Lovastatin reduced adhesion and rolling of leukocytes in brain vessels, inhibited blood-brain barrier disruption, and reversed decreases in cerebral capillary density. Lovastatin also inhibited ICAM-1 and CD11b mRNA expression while increasing HMOX-1 mRNA levels. Proinflammatory cytokines and markers of oxidative stress were lower in the brains of infected mice treated with lovastatin.

 

Lovastatin administered together with antimalarial drugs during the acute phase of the disease-protected survivors from impairment in both contextual and aversive memory 15 days after infection. Similar results were observed in a model of bacterial sepsis.

 

Our findings support the possibility that statins may be valuable pharmacologic tools in treatment of patients with neuroinflammation associated with severe systemic inflammatory syndromes. Clinical trials with statins in CM and sepsis should be speedily considered to examine this point.



Of course, what works in mice isn’t guaranteed to work in humans.  The authors caution:

 

These models may provide important insights into the pathogenesis of cognitive dysfunction associated with cerebral malaria and related disorders that may be relevant to human conditions [7]. While differences between murine models of CM and the human syndrome are often emphasized [10], [11], there are also important similarities [3], [7], [12][14]. Nevertheless, caution must be exerted when translating experimental findings to the clinical scenario.

 

 

The VOA has a nice write up of this study (see Mice Study Indicates Cholesterol Drug Might Help Treat Serious Malaria Cases), including an interview with one of the authors, who recommends that:

 

Zimmerman recommends lovastatin be added to treatments for malaria as well as for sepsis, a systemic blood infection commonly known as blood poisoning that sickens and threatens the lives of more people worldwide than cerebral malaria.

 


The problem with statins is that these are are cheap, generic drugs.  They provide little financial incentive for their manufacturers to mount expensive human trials in order to prove their effectiveness against malaria, pneumonia, sepsis, or influenza.

 

So, while the evidence continues to suggest benefits to using statins for `off label’ purposes,  real proof of their effectiveness may be a long time in coming.

Friday, December 28, 2012

Study: Weighing The Risks Of MRSA Colonization

colorized scanning electron micrograph (SEM) of MRSA

MRSA - Photo Credit CDC


# 6807

 

The CDC tells us, in their Definition of MRSA page, that:

 

While 25% to 30% of people are colonized* in the nose with staph, less than 2% are colonized with MRSA (Gorwitz RJ et al. Journal of Infectious Diseases. 2008:197:1226-34.).

*Colonized:
When a person carries the organism/bacteria but shows no clinical signs or symptoms of infection. For Staph aureus the most common body site colonized is the nose.

 

 

Although 2% doesn’t sound like a lot, there are signs that number may be increasing. Once considered primarily a hospital acquired infection, CA-MRSA (community acquired) is growing in incidence.

 

As an example, in Firefighters & Paramedics At Greater Risk Of MRSA and Firefighters & MRSA Revisited we looked at research showing a 10x’s greater incidence of MRSA colonization (20%) among a sampling of firefighters tested in Washington State.

 

Since one person’s colonization can become another person’s infection, topics of debate have included:

 

  1. What risks are there to the individual from long-term colonization?
  2. What risks are there to others In the Community or a household?
  3. What risks are there to others in a hospital or long-term care environment?
  4. What (if any) steps should be taken to decolonize carriers, and in what setting (hospital admission? Outpatient?) is decolonization desirable and effective?

 

There are, it seems, few easy answers. 

 

Mary McKenna, editor of the terrific Superbug Blog, took a look at the problems inherent with the decolonization of MRSA carriers in 2009 with:

 

Decolonization: disappointing news 


The upshot was that while studies have shown that decolonization procedures on hospitalized patients about to undergo surgery can reduce infections, the value to other patients is far less clear.

 

And as Maryn points out, overuse of mupirocin – the primary antibiotic used to decolonize patients –can lead to increased resistance over time.

 


And Mary also tells of a paper published in Infection Control and Hospital Epidemiology, that evaluated the success of decolonization protocols in 3 major Illinois hospitals, that less than reassuring results: a temporary reduction in patients’ being colonized with MRSA, but no success in preventing infection.

 

In 2011, the Infectious Diseases Society of America published their clinical practice guidelines for treating MRSA in adults and children, where they endorse `decolonization’, but only under select scenarios (note SSTI = Skin & Soft Tissue Infection):

 

  • 14. Decolonization may be considered in selected cases if:

    • i. A patient develops a recurrent SSTI despite optimizing wound care and hygiene measures (C-III).

    • ii. Ongoing transmission is occurring among household members or other close contacts despite optimizing wound care and hygiene measures (C-III).

     

    • ii. Contacts should be evaluated for evidence of S. aureus infection:
    • a. Symptomatic contacts should be evaluated and treated (A-III); nasal and topical body decolonization strategies may be considered following treatment of active infection (C-III).
    • b. Nasal and topical body decolonization of asymptomatic household contacts may be considered (C-III)
  •  

    But what, if anything, to do about asymptomatic carriers who are colonized, but not infected with MRSA remains up in the air.

     

    Hospital strategies to contain and control MRSA range from passive surveillance to aggressive `search & destroy’ policies – with variations in between.

     

    Passive surveillance – which is the most commonly used protocol in the United States – involves  testing only those who have clinical signs or symptoms of
    MRSA.

    Since patients may be colonized without exhibiting outward signs, this will fail to detect a great many carriers of the bacteria.

    Active Surveillance – requires the testing of high risk admissions (ie.  Hx of MRSA, Antibiotic Use, Admission to Hospital in past year, Resident of Long-term care facility, etc.) for the bacteria.

    Patients testing positive may be isolated and decolonized or treated, with strict infection control precautions enforced.

    Universal Surveillance – takes the above steps to a higher level, where all admissions and personnel are routinely swabbed and tested for MRSA.

    “Search & Destroy” – which is the most intensive protocol, has been used successfully in countries like Finland, Denmark and the Netherlands.

    It combines Active or Universal Surveillance with testing of patients in high-risk wards at intervals and prior to discharge.

     

    The reluctance to adopt the more aggressive of these measures have been the costs, the inconvenience to patients and their visitors, and quite frankly, objections by some hospital staff over being repeatedly tested.


    A recent study appearing in Critical Care Medicine, looked at the effects of a strict S&D policy instituted at a rural trauma center, and found an immediate reduction specific types of HAIs (Hospital Acquired Infections) after implementation.

     

    Search & Destroy (S&D): Eradication of Mrsa Colonization Is Associated With Decreased Mrsa Infections in Trauma Patients

    Borst, Gregory; Waibel, Brett; Toschlog, Eric; Coogan, Michael; Skarupa, David; Rotondo, Michael; Ramsey, Keith

    Conclusions: Search and destroy is associated with significant decreases in the incidence of MRSA VAP and CLABSI in trauma patients. Decreases in MRSA CAUTI and wound infections were also seen after the implementation of this program. Pre-emptive strategies to identify and eradicate MRSA are worthwhile endeavors in terms of preventing nosocomial infection.

     

    Despite its critics, S&D policies have often shown reductions in HAIs. 

     

    Which brings us to another study, published last week in the journal Antimicrobial Agents and Chemotherapy, that finds (among a relatively small cohort of patients) that colonization with MRSA posed a substantial risk of MRSA infection, increased mortality, or readmission to the hospital, compared to patients without MRSA colonization.

     

     

    Long-Term Risk for Readmission, Methicillin-resistant Staphylococcus aureus (MRSA) Infection, and Death among MRSA-Colonized Veterans.

    Quezada Joaquin NM, Diekema DJ, Perencevich EN, Bailey G, Winokur PL, Schweizer ML.

    Source

    Division of Infectious Diseases.

    Abstract

    Background: While numerous studies assessed outcomes of MRSA colonization over the short term, little is known about longer-term outcomes after discharge. An assessment of long-term outcomes could inform the utility of various MRSA prevention approaches.

    Methods: A matched cohort study was performed among Veterans Affairs (VA) patients screened for MRSA colonization between the years 2007 and 2009 and followed to evaluate outcomes until 2010. Cox proportional hazard models were used to evaluate the association between MRSA colonization and long-term outcomes such as infection-related readmission, and crude mortality.

    Results: 404 veterans were included, 206 of whom were MRSA carriers and 198 who were non-carriers. There were no culture-proven MRSA infections on readmission among the non-carriers, but 13% of MRSA-carriers were readmitted with culture proven MRSA infections on readmission (P<0.01).

    MRSA carriers were significantly more likely to be readmitted, be readmitted more than once due to proven or probable MRSA infections, and be readmitted within 90 days of discharge compared to non-carriers (p<0.05). Infection-related readmission (adjusted hazard ratio [AHR] =4.07; 95% confidence interval [CI]: 2.16, 7.67) and mortality (AHR=2.71; 95% CI: 1.87, 3.91) were significantly higher among MRSA carriers compared to non-carriers, after statistically adjusting for potential confounders.

    Conclusions: Among a cohort of VA patients, MRSA carriers are at high risk of infection-related readmission, MRSA infection and mortality compared to non-carriers. Non- carriers are at very low risk of subsequent MRSA infection. Future studies should address whether interventions such as nasal or skin decolonization could result in improved outcomes for MRSA carriers.

    Although based on a small cohort, this study suggests that being colonized (but not infected) with MRSA is a significant risk factor for future infection, and if these findings can be confirmed by others, may influence how MRSA colonization is viewed in the future.

     

    Despite some recent improvements in MRSA rates among hospitalized patients in the United States, HAIs (which include many other pathogens) continue to exact a heavy toll. This oft quoted assessment from the CDC on the burden of Hospital Acquired Infections in the United States is from 2010.

     

    A new report from CDC updates previous estimates of healthcare-associated infections. In American hospitals alone, healthcare-associated infections account for an estimated 1.7 million infections and 99,000 associated deaths each year. Of these infections:

    • 32 percent of all healthcare-associated infection are urinary tract infections
    • 22 percent are surgical site infections
    • 15 percent are pneumonia (lung infections)
    • 14 percent are bloodstream infection


    For more on MRSA, and many other antibiotic-resistant threats, you can do no better than to visit Maryn McKenna’s terrific Superbug Blog, and to read her book Superbug: The Fatal Menace of MRSA . . . which won last year’s  NASW Science in Society Journalism Award.

    You’ll find my review of her book HERE

    Thursday, December 27, 2012

    Resolve To Be Ready: 2013

     

    image

     

    # 6806

     

    Despite some of the negative images that `doomsday survivalist’ type TV shows have fostered, Ready.gov, FEMA, the HHS, and the CDC all promote the idea that everyone should be prepared to deal with a variety of emergencies and disasters.

     

    They know that every year tens of thousands of people across the nation are forced to deal with house fires, floods, severe storms, and medical emergencies. And the potential exists for even larger disasters like hurricanes, earthquakes, and even a pandemic. 

     

    Being better prepared - as an individual, family, and community - can save lives and reduce misery.

     

    With the start of a new year, many of us will be making New Year’s resolutions – which makes this the perfect time to join FEMA & Ready.gov’s  Resolve to Be Ready in 2013 campaign.

     

     

    This year, with the rapid proliferation of `smart phones’ & tablets, the focus is on incorporating these technologies into preparedness.

     

    Resolve to be Ready

    Led by FEMA's Ready campaign in partnership with Citizen Corps and the Ad Council, this year's emphasis includes integrating technology into individuals, families and businesses preparedness plans. A 2012 Nielson report revealed that nearly 55 percent of mobile phone owners in the United States own smartphones. As a simple resolution, Ready is asking all smartphone owners to turn the technology in their purses and pockets into a life-saving tool during and after an emergency or disaster.

     

    Below are additional ways the Ready campaign recommends implementing technology into your emergency plans:

    • Learn how to send updates via text and internet from your mobile phone to your contacts and social channels in case voice communications are not available;
    • Store your important documents such as personal and financial records in the cloud, in a secure and remote area, or on a flash or jump drive that you can keep readily available so they can be accessed from anywhere; and
    • Create an Emergency Information Document by using Ready's Family Emergency Plan template in Google Docs (use Google Chrome to view) or by downloading the Ready Family Emergency Plan to record your emergency plans.
    • Download the Resolve 2B Ready 2013 Toolkit for tips and actions you can take.

    A good starting place is FEMA’s App – available for Android, Blackberry, & Apple - which they describe as:

    image

    Government disaster response at the touch of a button. Learn how to respond to disasters, keep your family safe, apply for assistance, and help others in case of floods, hurricanes, earthquakes, terrorism, or other disasters. We continue to add new relevant information, in both English and Spanish, working to ensure that Americans have easy access to the tools they need to prepare for and, when needed, recover from a disaster in their community. Future enhancements include the ability to check on the status of an application and update an existing application.

     

    In October I highlighted some of the smart phone apps available from the American Red Cross (see Red Cross Apps). They include:

    Wildfire App

    First Aid App

    Hurricane App

    Shelter Finder App

    Earthquake App

     

    To become better prepared as an individual, family, business owner, or community requires more than just downloading an app, so I would invite you visit the following preparedness sites to learn the basics.

     

    FEMA http://www.fema.gov/index.shtm

    READY.GOV http://www.ready.gov/

    AMERICAN RED CROSS http://www.redcross.org/

     

    And finally, some of my own preparedness articles may be of interest:

     

    When 72 Hours Isn’t Enough

    In An Emergency, Who Has Your Back?

    An Appropriate Level Of Preparedness

    The Gift of Preparedness 2012

    Wednesday, December 26, 2012

    Referral: McKenna On MRSA In UK Milk

     

    image

    MRSA - Photo Credit – CDC PHIL 

    # 6805

     

     

    During the summer of 2011 news of a new strain of MRSA (Methicillin-resistant Staphylococcus aureus) found in milk in the UK made considerable headlines. 

     

    Although I wrote about it in UK: `New MRSA’ Strain Spreading, the real expert in all things antibiotic resistant in the blogosphere is Maryn Mckenna on her Superbug Blog, who provided in-depth coverage in More MRSA, in milk: A new strain in cows and humans.

     

    Today Maryn is back with another report, this time on the detection of the ST398 strain of MRSA, recently detected in Milk produced in England.

     

    Follow the link below to read:

     

    Livestock MRSA Found For First Time In UK Milk

    China: Avian-Origin Canine H3N2 Prevalence In Farmed Dogs

     

    image

    # 6804

     

     

    To western sensibilities, the raising of dogs (and cats) as food (or for their skins) is both cruel and barbaric, but for thousands of years these animals have been used for these purposes in many places around the world. (see IBTimes article China proposes ban on dog meat, will South Korea follow suit?).

     

    As with any livestock raised in close quarters, shipped unregulated cross-country, or kept under less than humane conditions, there is the potential for the introduction and spread of disease. 

     

    Today (h/t Tetano on FluTrackers) we’ve a study that looks at the seroprevalence of avian-origin H3N2 among farmed dogs in China. 

     

    But first, a little background on the virus.

     

    In July of 2011, in a blog called Korea: Interspecies Transmission of Canine H3N2, I wrote about a study that reported on a recently emerged canine H3N2 influenza virus that had been observed to infect and sicken domestic cats at an animal shelter in South Korea.

     

    This emerging canine H3N2 was of a different lineage than human H3N2 which appeared in the 1968 pandemic. It first appeared in Korea in 2007 – and unlike the other canine flu (H3N8)  -which jumped from equines to dogs, this strain appears to have emerged directly from an avian source.

     

    Earlier this year, in Interspecies Transmission Of Canine H3N2 In The Laboratory, we saw another study that showed that cats (and to a far lesser degree, ferrets) were susceptible to this canine H3N2.  Thus far, these new canine viruses haven’t shown the ability to infect humans.

     

    But viruses, particularly promiscuous ones that jump species, have ample opportunities to evolve and mutate. Which led the author of a  2008 EID study - Transmission of Avian Influenza Virus (H3N2) to Dogs - to point out:

     

    Transmission of avian influenza A virus to a new mammalian species is of great concern, because it potentially allows the virus to adapt to a new mammalian host, cross new species barriers, and acquire pandemic potential.

     

    The abstract to today’s study (slightly reparagraphed for readability) from the NIH’s PubMed.gov site, finds the newly emergent H3N2 CIV prevalent in pet and farmed dog populations in southern China. 

     

     

    Avian-origin H3N2 Canine Influenza Virus Circulating in Farmed Dogs in Guangdong, China.

    Su S, Li HT, Zhao FR, Chen JD, Xie J, Chen ZM, Huang Z, Hu Y, Zhang M, Tan L, Zhang GH, Li SJ.

    Source

    College of Veterinary Medicine, South China Agricultural University, Guangzhou, Guangdong Province 510642, People's Republic of China.

    Abstract

    Since 2006, more and more cases of the infectious H3N2 canine influenza virus (CIV) in pet dogs have been reported in southern China. However, little is known about the prevalence situation of H3N2 CIV infections in farmed dogs in China. This is the first systematic epidemiological surveillance of CIV in different dog populations in southern China.

     

    Two virus strains (A/canine/Guangdong/1/2011(H3N2) and A/canine/Guangdong/5/2011(H3N2) were isolated from canine nasal swabs collected at one dog farm in Guangzhou and the other farm in Shenzhen. Sequence and phylogenetic analysis of eight gene segments of these viruses revealed that they were most similar to the newly isolated canine H3N2 viruses in dogs and cats from Korea and China, which originated from avian strain.

     

    This indicates that H3N2 CIV may be a common pathogen for pet and farmed dog populations in southern China at present. Serological surveillance has shown that the infection rate of this avian-origin canine influenza in farmed dogs and in pet dogs were 12.22% and 5.3%, respectively; as determined by the ELISA. The data also suggested that transmission occurred, most probably by close contact, between H3N2 CIV infected dogs in different dog populations in recently years.

     

    As H3N2 outbreaks among dogs continue in the Guangdong province (located very close to Hong Kong), the areas where is densely populated and with frequent animal trade, there is a continued risk for pets H3N2 CIV infections and for mutations or genetic reassortment leading to new virus strains with increased transmissibility among dogs.

     

    Further in-depth study is required as the H3N2 CIV has been established in different dog populations and posed potential threat to public health.

     

     

    A recurring theme in this blog is that nature’s lab is open 24/7, and is constantly trying out new genetic experiments. 

     

    For a virus, successfully jumping to a new species is akin to hitting the lottery. A fresh supply of hosts not only increases its odds of long-term survival, it may also provide new opportunities for evolution.

     

     

    Which is why we give these species jumps considerable attention.

    ‘Tis The Season For Avian Flu

     

    image

    Seasonality of H5N1  Source FAO  H5N1 HPAI Global Overview

     

    # 6803

     

     

    In recent weeks we’ve been following reports of massive duck die offs in Indonesia, supposedly linked to the arrival of clade 2.3.2 of the H5N1 virus (see VOA Report On The Indonesian Duck Die Off), but with cooler weather bird flu activity is on the rise in other places around the world as well.

     

    The chart above shows the `seasonality’ of bird flu outbreaks in poultry, with generally a lull seen during the summer and early fall, and a peak in the winter to late spring.

     

    The same pattern can be seen with human cases, as illustrated by the following chart from the World Health Organization’s Influenza at the human–animal interface report from September of this year.

     

    image

     

    Not unexpectedly, two countries often plagued by H5N1 outbreaks in recent years are reporting reoccurrences this week; Bangladesh and Nepal.

     

    First stop Nepal, where an outbreak of bird flu is being reported in the capital, Kathmandu.  We saw reports of an outbreak last October (see Nepal: H5N1 Outbreak In Poultry) in two eastern provinces; Sumari and Ilam.

     

    image

     

    Bird flu confirmed in a Kathmandu farm

    REPUBLICA

    2,500 chickens die; 19,000 eggs destroyed


    KATHMANDU, Dec 25: The rapid response teams of District Animal Health Office Kathmandu on Tuesday destroyed over 19,000 eggs after bird flu was confirmed in a Kathmandu-based poultry farm.

     

    The central veterinary laboratory under the Directorate of Animal Health (DoAH) had confirmed bird-flu virus in the poultry farm owned by Subirman Singh Basnet of Ramkot-6, Kathmandu two days ago.

     


    (Continue . . . )

     

     

    Meanwhile, in Dhaka, Bangladesh - 600 to the east - authorities are combating what they are calling the worst outbreak of avian flu in 5 years.  This report from AFP.

     

    Wednesday December 26, 2012

    Bangladesh slaughters 150,000 birds over avian flu

    DHAKA: Bangladesh's livestock authorities are slaughtering around 150,000 chickens at a giant poultry farm near Dhaka after the worst outbreak of avian flu in five years, officials said Wednesday.

     

    The deadly H5N1 strain of flu was detected at Bay Agro farm at Gazipur, 40 kilometres (25 miles) north of Dhaka, on Monday after dozens of chickens died, prompting the company to send samples to a laboratory for tests.

    (Continue . . . )

     

    And over the past several weeks we’ve seen numerous reports of H5N1 in poultry in Egypt.  A partial listing of recent outbreaks from the FAO EMPRES-i RSS feed includes:

     

    image   

     

    While many countries have managed to control, or even eradicate, the H5N1 virus - outbreaks in poultry remain fairly common in places like Egypt, Indonesia, India, Vietnam, Bangladesh, and even Nepal.

     

    For now, these outbreaks pose only a limited public health hazard, as this avian virus remains poorly adapted to human physiology. Human infections remain rare, but when they are reported, they often end up being fatal.

     

    The concern is that one of these days the virus will `figure us out’, and learn how to transmit efficiently from human to human. It may never happen, or it could happen tomorrow.

     

    Which is why we follow outbreaks in wild and domesticated birds, along with rare human infections, with considerable interest.

    Monday, December 24, 2012

    A Flu Near You Snapshot

     

     

    # 6802

     

    Yesterday I highlighted the latest CDC FluView report – for the week of December 9th-15th – that indicated continued increases in flu activity around the country.

     

    These reports are essentially a snapshot of flu activity as it was being reported a week or 10 days ago.

    image

    Week 50 ILI activity – Source CDC FluView

     

    Doctors, epidemiologists, and other public health officials would prefer a more current status report, but collecting, collating, and analyzing data takes time. 

     

    So these reports are always a week or so behind.

     

    One recent attempt to use the internet to track influenza activity is the Flu Near You project, which I’ve written about in the past. Run by Healthmap of Children’s Hospital Boston in partnership with the American Public Health Association and the Skoll Global Threats Fund, this project maps self-reported influenza-like-illness from its volunteers.

     

    While self-reported flu symptom surveys cannot replace traditional influenza testing and surveillance methods, they can hopefully give us a more up-to-date idea of respiratory illness trends.

     

    And judging by the latest Flu Near You map (current as of 9:15am EST Dec 24th), ILI’s are showing no sign of slowing across the nation.

     

    image

     

    As the number of participants grows, it is hoped that this project will become a more reliable indicator of current ILI activity around the nation.

     

    For more on this project, and information on how you can participate, see Do You Have It In You?

     

    Meanwhile, now is the time to take those extra steps to try to protect yourself (and others) against the flu, and other viral diseases. 

     

    • Washing your hands often
    • Covering coughs and sneezes
    • Staying home if you are sick.

     

    And finally, to all of my friends and  readers around the world, I wish you a happy, healthy, and joyous holiday season.

    Sunday, December 23, 2012

    FluView, FluWatch, And WHO Flu Surveillance Reports

    image

    Week 50 ILI activity – Source CDC FluView

     

    # 6801

     

    Regardless of your preferred type of celebration (Christmas, Hanukah, Kwanzaa, the Winter Solstice, Festivus . . .) the winter holiday season often finds us gathered together in relatively closed quarters to share presents, good times, and far too often . . . germs.

     

    All of which makes this week’s FluView from the CDC, Canada’s FluWatch, and World Health Organization bi-weekly Influenza Summary of particular interest.

     

    The early start to this year’s flu season continues across much of the United States, with A/H3N2 by far the predominate strain being reported. While it is a bit early to talk about the severity of this year’s flu season, historically H3N2 dominated seasons have typically produced more severe illness.

     

    First stop, the CDC’s FluView Report for week 50.

     

    2012-2013 Influenza Season Week 50 ending December 15, 2012

    All data are preliminary and may change as more reports are received.

    Synopsis:

    During week 50 (December 9-15), influenza activity increased in the U.S.

    • Viral Surveillance: Of 9,562 specimens tested and reported by U.S. World Health Organization (WHO) and National Respiratory and Enteric Virus Surveillance System (NREVSS) collaborating laboratories in week 50, 2,709 (28.3%) were positive for influenza.
    • Pneumonia and Influenza Mortality: The proportion of deaths attributed to pneumonia and influenza (P&I) was below the epidemic threshold.
    • Influenza-Associated Pediatric Deaths: Two influenza-associated pediatric deaths were reported. One was associated with an influenza A (H3) virus and one was associated with an influenza A virus for which the subtype was not determined.
    • Outpatient Illness Surveillance: The proportion of outpatient visits for influenza-like illness (ILI) was 3.2%; above the national baseline of 2.2%. Nine of ten regions reported ILI above region-specific baseline levels. Twelve states experienced high ILI activity, New York City and 5 states experienced moderate ILI activity; 11 states experienced low ILI activity; 22 states experienced minimal ILI activity, and the District of Columbia had insufficient data.
    • Geographic Spread of Influenza: Twenty-nine states reported widespread geographic influenza activity; 12 states reported regional activity; the District of Columbia and 5 states reported local activity; 3 states reported sporadic activity; Guam reported no influenza activity, and Puerto Rico, the U.S. Virgin Islands, and 1 state did not report.

    A description of surveillance methods is available at: http://www.cdc.gov/flu/weekly/overview.htm

     

    The following graphic shows just how early detection of influenza has been this year (red line), compared to previous years.

    image

     


    Meanwhile, Canada’s FluWatch report indicates that influenza is beginning to ramp up in several provinces as well.

     

    image

    Overall Influenza Summary

    • Influenza activity in Canada continued to increase in week 50; four regions reported widespread activity, and the majority of regions reported influenza circulation.
    • A total of 1502 laboratory detections of influenza were reported, of which 96.7% were for influenza A viruses, predominantly A(H3N2).
    • Thirty-one influenza outbreaks were reported: 24 in long-term-care facilities, 4 in hospitals and 3 in other facilities.
    • Thirty-three paediatric influenza-associated hospitalizations were reported through the IMPACT network, all but one with influenza A
    • Seventy-three hospitalizations with three deaths in adults ≥20 years of age were reported through Aggregate surveillance, all with influenza A.
    • The ILI consultation rate increased compared to the previous week and is within the expected range for this time of year.

     

    Virus characterization from Canada shows, like the United States, that A/H3N2 makes up the bulk of identified samples.

     

    image


    And globally, influenza rates in the Northern Hemisphere are beginning to rise, although many areas are lagging somewhat behind the numbers seen in North America. 


    This from the World Health Organization.

     

    Influenza update

    21 December 2012 - Update number 175

    Summary

    • Many countries in the temperate regions of the northern hemisphere are now reporting elevated detections of influenza, particularly in north America.

     
    • Influenza activity was still low in Europe, with co-circulating of both influenza A and B viruses. However increased influenza-like illnesses were reported in more countries than previous weeks.


    • There was low, but increasing influenza activity in northern Africa and the Eastern Mediterranean regions, and sporadic detections in eastern Asia.

    • Influenza in central America, the Caribbean and tropical south America continued to decline, with low levels of circulation of mainly influenza A(H3N2) and some influenza B viruses, except for Cuba and Peru, where influenza A(H1N1)pdm09 was predominant.

    • Influenza activity in Sub-Saharan Africa declined to low levels, with mainly influenza B, except in Ghana, where influenza A(H1N1)pdm09 was reported.

    • Influenza in most South East Asian countries was declining, except in Sri Lanka and Viet Nam.
    • Influenza activity in the temperate countries of the southern hemisphere continued at inter-seasonal levels.

     

    The CDC recommends a flu shot for just about everyone each year, but regardless of whether you received one, this Holiday season is a good time to hone your basic flu hygiene skills.  

     

    The CDC recommends:

     

    Take everyday preventive actions to stop the spread of germs.

    • Cover your nose and mouth with a tissue when you cough or sneeze. Throw the tissue in the trash after you use it.
    • Wash your hands often with soap and water. If soap and water are not available, use an alcohol-based hand rub.*
    • Avoid touching your eyes, nose and mouth. Germs spread this way.
    • Try to avoid close contact with sick people.
    • If you are sick with flu–like illness, CDC recommends that you stay home for at least 24 hours after your fever is gone except to get medical care or for other necessities. (Your fever should be gone without the use of a fever-reducing medicine.)
    • While sick, limit contact with others as much as possible to keep from infecting them.

     

    As an added bonus, these healthy hygiene habits can also help protect you against the other winter time scourge, Norovirus – which, like influenza, can wreck a family holiday gathering in record time.